Physician profile
Mushtaq Mahmood
NPI 1497733075
$837.80
in general payments reported to CMS, 2019-2025
12 companies · $713 in 2025
The $713 reported for 2025 was more than what 82% of Adolescent Medicine (Internal Medicine) providers received nationally (typical 2025 total: $165).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $125 · 2025: $713.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $838.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $837.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $245.81 | 2025 | |
| Glaxosmithkline, LLC. | $125.00 | 2023 | Shingrix |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $110.15 | 2025 | Lifevest |
| Heartflow, INC. | $105.49 | 2025 | |
| Pfizer INC. | $78.70 | 2025 | |
| Dexcom, INC. | $48.14 | 2025 | Dexcom G6 Transmitter |
| Aimmune Therapeutics, INC. | $31.02 | 2025 | Zenpep |
| Exact Sciences Corporation | $26.93 | 2025 | The Cologuard Plus Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $19.35 | 2025 | Camzyos |
| Amgen INC. | $18.05 | 2025 | Repatha |
| Astrazeneca Pharmaceuticals Lp | $14.60 | 2025 | Airsupra |
| Astellas Pharma US INC | $14.56 | 2025 | Veozah |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mushtaq Mahmood listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.